Anupam Rasayan Reports 21% Revenue Growth in H1 FY27 at ₹1,489 Crore

AnupamRasayan_Provide_EVChemicals
Image Courtesy: Anupam Rasayan

Anupam Rasayan India Limited (BSE: 543275; NSE: ANURAS) reported a 21% year-on-year increase in consolidated revenue to ₹1,489 crore for the half year ended September 30, 2026, compared with ₹1,230 crore in the corresponding period last year. EBITDA, including other income, increased 38% to ₹377 crore from ₹273 crore in H1 FY26. The EBITDA margin improved to 25% from 22% in the year-ago period. Profit after tax (PAT) stood at ₹116 crore, against ₹106 crore in H1 FY26, registering a growth of 10%.

For the second quarter of FY27, the company recorded its highest-ever quarterly consolidated revenue of ₹821 crore, an increase of 11% over ₹739 crore in Q2 FY26. EBITDA rose 41% to ₹202 crore from ₹144 crore, while the EBITDA margin improved to 25% from 19%. PAT increased 14% to ₹65 crore compared with ₹57 crore in the corresponding quarter last year.

Commenting on the results, Anand Desai, Managing Director, Anupam Rasayan India Limited, said, “H1 FY27 was marked by steady progress across our strategic priorities, expansion into new end markets and continued strengthening of our business portfolio. We are pleased to have achieved our highest-ever quarterly consolidated revenue during Q2 FY27, reflecting the resilience of our diversified business and the progress made across key segments.

“Our focus continues to remain on building a globally integrated specialty chemicals platform by deepening relationships with existing customers, expanding into new applications and strengthening our capabilities across Pharmaceuticals, Performance Materials and other specialised segments.”

During the quarter, Anupam Rasayan signed a six-year long-term supply agreement with a US-based speciality metal manufacturer. The agreement marks the company’s entry into the geological resources sector and adds a new customer segment to its business portfolio.

The company also completed the acquisition of a 50.07% stake in Bliss GVS Pharma, securing a controlling interest. The acquisition expands its presence in pharmaceuticals by adding capabilities in finished dosage formulations and provides opportunities to develop its pharmaceutical business across the value chain.

The company plans to focus on integrating its strategic investments, improving capital utilisation and strengthening manufacturing and technological capabilities. It will also continue to expand customer relationships and develop applications across its existing business segments.

Anupam Rasayan operates in custom synthesis and manufacturing of specialty chemicals, serving customers in India and international markets. Its business covers life sciences-related specialty chemicals, including agrochemicals, personal care and pharmaceuticals, as well as performance materials for electronics, electric vehicles and polymers.

Incorporated in 1984, Anupam Rasayan India Limited is engaged in custom synthesis and manufacturing of specialty chemicals. The company serves more than 200 domestic and international customers through 14 manufacturing facilities, including six in Gujarat, six in Maharashtra, one in Tamil Nadu and one in the United States. As of September 30, 2026, it had an aggregate installed capacity of more than 2,00,000 MT for specialty chemicals and over 4,800 million units for pharmaceutical formulations. Its operations involve multistep synthesis and complex chemical reactions for a range of industrial applications.